Medicare AdvantagePrior AuthMedium impact
Qbrexza® (glycopyrronium) Cloth (New)
Humana·Dermatology, Family Medicine, Internal Medicine·Medicare Advantage
Effective date
Jul 23, 2025
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage now requires prior authorization for Qbrexza (glycopyrronium) cloth for hyperhidrosis treatment starting July 23, 2025. Patients must meet three specific criteria including 6-month primary axillary hyperhidrosis diagnosis, HDSS rating of 3-4, and failed conventional treatment.
Action Required
By July 23, 2025: Providers treating hyperhidrosis must obtain prior authorization before prescribing Qbrexza for Medicare Advantage patients. Document all three required criteria: 6-month primary axillary hyperhidrosis diagnosis, HDSS rating of 3 or 4, and previous treatment failure with conventional therapies (aluminum chloride 20% antiperspirant or oral oxybutynin). Update clinical documentation templates to capture these requirements. Prescriptions without prior auth will be denied.